Daewoong Pharmaceutical Co. LTD. is advancing DWP16001 through a Phase 3 clinical trial aimed at demonstrating its long-term safety and efficacy in T2DM patients. The market for diabetes therapeutics is substantial, with increasing prevalence driving demand for effective treatments. DWP16001's positioning as an adjunct therapy for patients inadequately controlled on existing medications may provide a competitive edge, particularly in markets with high unmet needs. The trial's outcomes could significantly influence Daewoong's market share and revenue potential in the diabetes sector, contingent upon successful results and subsequent regulatory approvals.